- Home
- AQST
as 11-15-2024 3:30pm EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 502.6M | IPO Year: | 2018 |
| Target Price: | $9.43 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.69 - $6.23 | Next Earning Date: | 11-04-2024 |
| Revenue: | $58,900,000 | Revenue Growth: | 22.56% |
| Revenue Growth (this year): | 18.45% | Revenue Growth (next year): | -9.00% |
Latest Aquestive Therapeutics Inc. News
AQST Breaking Stock News: Dive into AQST Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?
GlobeNewswire
5 days ago
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Simply Wall St.
11 days ago
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
11 days ago
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
Zacks
13 days ago
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks
13 days ago
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
13 days ago
Aquestive Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
13 days ago
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Compare AQST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.